Afrezza denied as not medically necessary by Humana?

Humana's specific coverage criteria for afrezza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Afrezza on Medical-Necessity Grounds

Afrezza (inhaled insulin) is FDA-approved for glycemic control in adults with diabetes, but Humana frequently issues medical-necessity denials when the clinical record does not clearly document why an injectable insulin formulation is insufficient or inappropriate for the patient. Reviewers often conclude that conventional insulin delivery meets the same clinical need, and they deny Afrezza as a convenience preference rather than a medical requirement.

## Why This Denial Is Appealable

A medical-necessity determination is not final. Under ACA Section 2719 and its implementing regulations, you have the right to a full internal appeal followed by independent external review through a federally accredited Independent Review Organization (IRO). If your plan is self-funded under ERISA, Section 503 guarantees a full-and-fair review with access to the specific clinical criteria used. Most plans allow approximately four months from the date of denial to request external review, and an expedited track (typically 72-hour turnaround) is available when standard timelines would seriously jeopardize health.

## What Drives a Successful Appeal

The core task is demonstrating — in the language of Humana's own published medical policy — that Afrezza is medically necessary for this patient, not merely preferable. To do that:

1. Confirm the diagnosis and severity. Gather recent A1C values, glucose logs, and any hypoglycemia incident records from the chart. Document the clinical picture in the prescriber's own words.

2. Document the injectable insulin history. For each prior insulin formulation tried, record the start date, stop date, doses used, and the specific clinical outcome (inadequate control, recurrent hypoglycemia, injection-site complications, documented needle phobia, etc.). Humana reviewers look for a clear trail showing why conventional options were tried and found inadequate.

3. Obtain a detailed medical-necessity letter from the prescribing clinician. The letter should explain the individualized clinical rationale — not a generic statement — and should directly address each criterion in Humana's coverage policy for Afrezza. Retrieve that policy from Humana's provider portal or by requesting it in writing; policies are updated periodically and the version that applies to your denial date controls.

4. Verify eligibility criteria against the FDA label. The FDA-approved prescribing information for Afrezza specifies the indicated patient population and any clinical conditions relevant to use. Confirm with the prescriber that the patient meets every criterion stated in the label, and that the chart reflects this explicitly.

5. Map the record to each policy requirement. Create a simple two-column table: left column lists each criterion from Humana's policy verbatim; right column cites the specific chart entry, lab result, or clinical note that satisfies it. This structure makes the reviewer's job easy and leaves no requirement unanswered.

## Timeline

• Internal appeal: Submit within the timeframe stated on the denial notice (commonly 180 days). Expect a decision within 30–60 days, or 72 hours on expedited review.
• External review: Request within approximately four months of the final internal denial. The IRO is independent of Humana and applies clinical, not administrative, standards.

## Key Documents to Gather

• Denial letter (note the specific criteria cited)
• Humana's current medical policy for Afrezza (request from Humana directly)
• FDA prescribing label for Afrezza
• Complete diabetes medication history with dates and documented outcomes
• Recent lab work and glucose monitoring records
• Prescriber's individualized medical-necessity letter
• Any applicable ADA guideline references your clinician considers relevant to your case